TDM of Axitinib, Cabozantinib and Lenvatinib in patients with renal cell carcinoma

TDM of Axitinib, Cabozantinib and Lenvatinib in patients with renal cell carcinoma - CaLAx-TDM Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00035755

Enrollment

Registered

2026-02-05

Start date

2026-03-01

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C64

Interventions

Group 1: Therapeutic Drug Monitoring of Axitinib, Cabozantinib and Lenvatinib in patients with renal cell carcinoma Duration of trial: 1,5 years blood test related to trial before every treatment

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Treatment with Axitinib, Cabozantinib or Lenvatinib in patients with metastatic renal cell carcinoma - have full legal capacity - are of legal age (age > 18 years) - have given written consent to the study or have given consent to the BIOMASOTA database

Exclusion criteria

Exclusion criteria: unable to participate in trials

Design outcomes

Primary

Measure	Time frame
Concentration of Axitinib, Cabozantinib and Lenvatinib	—

Secondary

Measure	Time frame
Concentration of thyrosine kinase inhibitors Correlation between serum concentration and treatment-related adverse events Influence of treatment on bioavailability of thyrosine kinase inhibitors	—

Countries

Germany

Contacts

Public ContactKarsten Müller

Klinische Pharmakolgie Uniklinik Köln

carsten.mueller@uk-koeln.de+492214785066

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026